doi: 10.1136/bmjdrc-2020-001279 3 O'HaraAMShanahanF
00:19:28 Narrator If you found this episode helpful, follow Clinical Capsules or leave a quick rating or review
Plant-based dietary patterns and the risk of dementia: a population-based study
CRF-BP acts as an inhibitor of both CRF and the urocortins, thereby, modulating the biological actions of these peptides
Key highlights: Demonstrated sustained improvements across symptomatic, clinical, endoscopic, histologic, and quality-of-life endpoints Benefits seen even in ~27% of patients who had failed prior biologics or advanced therapies Long-term safety profile consistent with prior findings no new safety signals Among patients continuing from blinded maintenance to the open-label extension, 12% reported serious adverse events, 7% discontinued due to adverse events Approved for UC and Crohns disease in 44 countries These results (from the LUCENT-3 extension) were shared at UEG Week 2025 in Berlin and mark a significant milestone in the pursuit of durable, steroid-free remission for IBD patients
